The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

Having multiple treatment options is the kind of advancement we’ve all been waiting for ... scientists and clinicians ...

Alzheimer's disease begins with a long period during which abnormal amyloid and tau proteins build up in the brain without ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according to a report. The report by GlobalData, a data and analytics company, showed ...

Alzheimer’s disease (AD ... infrastructure for AD treatment, including blood biomarkers (BBMs) for diagnosis. A new era of AD AD is a progressive neurodegenerative disease with a continuum ...

Some people may also benefit from treatment options that don't involve medication ... We examine the three most promising drugs for the treatment of Alzheimer’s disease and summarise their journeys so ...

As a clinical stage company, SciNeuro is focused on developing precision medicine therapies to treat a wide spectrum of neurodegenerative conditions, including Alzheimer’s disease (AD ...

For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...

The treatment is not a permanent fix for Alzheimer's dementia, Jing said, because the disease will eventually ... It's important for them to know there are options out there." ...

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b ...

The European Medicines Agency has said no to approving a new drug for Alzheimer's disease in the EU ... thousands of people are left with no treatment options. The drug - the first new treatment ...